Cargando…
Assessing Time in Range with Postprandial Glucose-Focused Titration of Ultra Rapid Lispro (URLi) in People with Type 1 Diabetes
INTRODUCTION: To assess time in range (TIR) (70–180 mg/dL) with postprandial glucose (PPG)-focused titration of ultra rapid lispro (URLi; Lyumjev®) in combination with insulin degludec in people with type 1 diabetes (T1D). METHODS: This phase 2, single-group, open-label, exploratory study was conduc...
Autores principales: | Bergenstal, Richard M., Bode, Bruce W., Bhargava, Anuj, Wang, Qianqian, Knights, Alastair W., Chang, Annette M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570246/ https://www.ncbi.nlm.nih.gov/pubmed/37740871 http://dx.doi.org/10.1007/s13300-023-01476-4 |
Ejemplares similares
-
Increased Time in Range with Ultra Rapid Lispro Treatment in Participants with Type 2 Diabetes: PRONTO-Time in Range
por: Bailey, Timothy S., et al.
Publicado: (2023) -
Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy
por: Malecki, Maciej T., et al.
Publicado: (2020) -
Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO‐Pump‐2
por: Warren, Mark, et al.
Publicado: (2021) -
Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects
por: Linnebjerg, Helle, et al.
Publicado: (2020) -
Efficacy and safety of ultra‐rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO‐Peds trial
por: Wadwa, R. Paul, et al.
Publicado: (2022)